Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDR
The experimentally established mechanism targets of Brivanib Alaninate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 5/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 16/20 | 0.75 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.75 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.75 |
| ▸ | FGFR4 known ✓ | P22455 | 1/20 | 0.75 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.75 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 2/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivanib Alaninate SCHEMBL13108648 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL2263525 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL18319845 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL28365380 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29355920 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29665039 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL15971686 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13412331 | 0.95 | CYP3A4 (0.91) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3450304 | 0.93 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8207945 | 0.91 | CYP3A4 (0.84) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3957329-B1 | COMPOSITION COMPRISING THE COMBINATION OF SOTAGLIFLOZIN AS THE SODIUM/GLUCOSE CO-TRANSPORTER 1 INHIBITOR (SGLT1) AND A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR (VEGFR2) FOR USE IN TREATING CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-11-19 | — | — | EP | claimed |
| EP-3957310-B1 | COMPOSITION COMPRISING SOTAGLIFLOZIN AND A TYROSINE KINASE ACTIVITY INHIBITOR FOR USE IN THE TREATMENT OF CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-05-21 | — | — | EP | claimed |
| EP-2182078-B1 | Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | claimed |
| EP-1534290-B1 | NOVEL INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2011-12-21 | — | — | EP | claimed |
| US-8067189-B2 | Methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators by measuring the level of collagen type IV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | claimed |
| EP-2182078-A1 | Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators | Brystol-Myers Squibb Company (US) | 2010-05-05 | — | — | EP | claimed |
| EP-4735050-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735037-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | NOVARTIS AG (CH) | 2025-12-18 | — | — | US | disclosed |
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-09-16 | — | — | US | disclosed |
| US-20250250315-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | UNIV UTAH RES FOUND (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250195575-A1 | CHIMERIC TIM RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20070249610-A1 | PROCESS FOR THE PREPARATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20070088035-A1 | Crystalline forms of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088035-A1 | Crystalline forms of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| WO-2007038648-A1 | CRYSTALLINE FORMS OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | FGFR1 2593/4885KDR 4219/4885FLT1 4392/4885 |
| US-20070249610-A1 | PROCESS FOR THE PREPARATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER | ALDH7A1, MAT1A, IMPDH1 | FGFR1 340/4885KDR 1706/4885FLT1 817/4885 |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | CD2, CD2BP2, CD22 | FGFR1 1522/4885KDR 1015/4885FLT1 3010/4885 |
| US-20070088035-A1 | Crystalline forms of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester | NAP1L1, RCC1, ACIN1 | FGFR1 24/4885KDR 2800/4885FLT1 269/4885 |
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | CD47, CD2, CD58 | FGFR1 2219/4885KDR 2421/4885FLT1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.